/BTG/media/Main/Slider/cirse_2018_dc_bead_lumi.png?ext=.png

BTG @ CIRSE 2018

<p class="hidden-xs" style="text-shadow: 0px 0px 20px rgb(0, 0, 0);">Find out more about our Educational Sessions,<br /> Learning Centre and Workshops<br /> <br /> <em>Lisbon, Portugal<br /> <strong>22-25 SEPT 2018</strong></em></p> <a class="light-blue-btn hidden-xs" href="https://www.btgmeetings.com/CIRSE-2018" target="_blank">Learn More</a>

/BTG/media/Main/Slider/slide_6.png?ext=.png

UTILITY BEYOND VISIBILITY

VISION <span style="color: #533e7b">></span> PRECISION <span style="color: #533e7b">></span> ASSURANCE

/BTG/media/Main/Slider/Slide_1.jpg?ext=.jpg

a new level of control

The next-generation development of the gold-standard DC Bead™ has landed

/BTG/media/Main/Slider/slide_2.jpg?ext=.jpg

a new level of control

DC Bead LUMI™ offers lasting radiopacity combined with CE Mark approved indication for drug loading

SEE MORE TREAT SMARTER

CBT ≤ 90 mins post LUMI-TACE

This case was impressive because of the clear visualisation of the tumour and the embolised vessels on the post-embolisation non-contrast CBCT, in addition to the complete response of the related lesions.

CBT 10 mins post LUMI-TACE

After 4 weeks of follow-up, a complete response on mRECIST was demonstrated with a decrease in tumour size to 0.9 mm.

CT post LUMI-TACE

The radiopaque property of DC Bead LUMI™ allows for accurate needle placement and full lesion ablation. If the lesion cannot be seen on non-contrast CT, there is a possibility that the lesion may not be fully ablated.

DC Bead Lumi KOL

 
Building on the established clinical performance of DC Bead®, DC Bead LUMI comprises a radiopaque moiety1, allowing for a more precisely controlled procedure and the opportunity to revolutionize the treatment of hypervascular tumors and arteriovenous malformations (AVMs).

Register for updates